Biotech entity
clinical-trial is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention Dr. Marc Siegel, the most common co-covered peer. The 174-day window averages about 0.1 stories each week. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: 5d ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention Dr. Marc Siegel, the most common co-covered peer. The 174-day window averages about 0.1 stories each week. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. Their average consequence score of 6.5 runs above the beat's 6.1 for that window. We currently track 2 Biotech stories that mention Massachusetts General Hospital, published between February 26, 2026 and August 18, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 660 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Massachusetts General Hospital. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected window for preliminary safety and biomarker data review by the trial committee.
Dosing Initiation
First patient dosed with NUZ-001 in the multi-center Phase 2/3 study.
Trial Selection
NUZ-001 selected as a new regimen for the HEALEY ALS Platform Trial.
Diagnosis-to-treatment intervals grew for six early-stage cancers from 2012–2023, with lung (+12 days) and stomach (+14 days) leading. For biopharma, longer real-world waits threaten neoadjuvant therapy windows and perioperative trial design.
Source: fox7austin.com · fox32chicago.com
Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.
Source: sydneysun.com · malaysiasun.com
Massachusetts General Hospital is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
